NCT06790303 2025-06-04
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
GlaxoSmithKline
Phase 2 Terminated
GlaxoSmithKline
RAPT Therapeutics, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
AbbVie